Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial. (Q43924084)

From Wikidata

Jump to navigation Jump to search

scientific article published on 22 September 2017

Language	Label	Description	Also known as
English	Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.	scientific article published on 22 September 2017

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Plasmodium falciparum

0 references

0 references

malaria vaccine

1 reference

based on heuristic

inferred from title

Mathilde Bahuaud

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

author name string

S B Sirima

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

C Durier

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

L Kara

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

S Houard

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

A Gansane

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

P Loulergue

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

N Benhamouda

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

I Nebié

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

B Faber

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

E Remarque

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

O Launay

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

AMA1-DiCo Study Group

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

language of work or name

0 references

publication date

22 September 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

35

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

6218-6227

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

45

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Apical membrane antigen 1: a malaria vaccine candidate in review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

The Fab fragments of monoclonal IgG to a merozoite surface antigen inhibit Plasmodium knowlesi invasion of erythrocytes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT™ protects against blood-stage challenge in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Specificity of the protective antibody response to apical membrane antigen 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

A field trial to assess a blood-stage malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HTTM and Montanide ISA 51 in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Malaria morbidity in high and seasonal malaria transmission area of Burkina Faso

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Clinical Variation of Plasmodium falciparum eba-175, ama-1, and msp-3 Genotypes in Young Children Living in a Seasonally High Malaria Transmission Setting in Burkina Faso

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Production, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic Variation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Pitfalls in anti-influenza T cell detection by Elispot using thimerosal containing pandemic H1N1 vaccine as antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.027

7 January 2021

Identifiers

10.1016/J.VACCINE.2017.09.027

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28947345%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43924084&oldid=2104422370"